Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis.
about
Adverse effects of biologics: a network meta-analysis and Cochrane overview2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitisEfficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE).Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumabA multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis.The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agentsLong-term use of adalimumab in the treatment of rheumatic diseases.Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.Randomized, placebo controlled and double-blind trials of efficacy and safety of adalimumab for treating ankylosing spondylitis: a meta-analysis.Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.Upregulation of BMP-2 expression in peripheral blood mononuclear cells by proinflammatory cytokines and radiographic progression in ankylosing spondylitis.[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures].
P2860
Q24234197-C9AD6ECB-6779-41BB-8DBD-112BB1DE121BQ24603648-BFFC408D-20ED-48BD-8638-439A14E74821Q34758808-07F9D9D9-A38E-4010-B0FF-75E67D2AEE42Q35759171-C4648F10-C604-4575-AB69-60553B0C8F0BQ36157440-83BE453F-6860-40A8-9AD0-18FE0FC984F8Q37301134-257182A9-28CF-4F86-8383-E2DE308C804DQ37358124-5ABD2951-29D6-4A62-A337-A217D816F17BQ37873493-C6934DF0-5A69-4727-BE31-6EC8EF284802Q38145501-18241EFA-14B7-4AB0-8545-836CA423DE15Q38186145-69723B69-C588-4C0A-934E-948069AC6B03Q38993250-E0475C62-65CF-4587-9414-111DE9D86C27Q48086650-A037B9D0-0691-4BC0-8F2B-64C224F80A4DQ52874129-51B3C77F-38B2-447D-97BC-879255579C4F
P2860
Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Adalimumab effectively reduces ...... s with total spinal ankylosis.
@en
type
label
Adalimumab effectively reduces ...... s with total spinal ankylosis.
@en
prefLabel
Adalimumab effectively reduces ...... s with total spinal ankylosis.
@en
P2093
P2860
P356
P1476
Adalimumab effectively reduces ...... s with total spinal ankylosis.
@en
P2093
A L Pangan
ATLAS Study Group
E Collantes
M Borofsky
M H Schiff
P2860
P304
P356
10.1136/ARD.2007.082529
P407
P577
2007-12-04T00:00:00Z